Rhumbline Advisers Nuvation Bio Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 266,383 shares of NUVB stock, worth $713,906. This represents 0.0% of its overall portfolio holdings.

Number of Shares

266,383

Previous 260,939 2.09%

Holding current value

$713,906

Previous $761,000 19.58%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$2.3 - $3.83 $12,521 - $20,850	5,444 Added 2.09%	266,383 $612,000
Q2 2024 Aug 01, 2024	BUY	$2.58 - $3.69 $137,743 - $197,005	53,389 Added 25.72%	260,939 $761,000
Q1 2024 May 09, 2024	SELL	$1.46 - $3.97 $4,010 - $10,905	-2,747 Reduced 1.31%	207,550 $755,000
Q4 2023 Feb 08, 2024	SELL	$0.96 - $1.53 $3,791 - $6,041	-3,949 Reduced 1.84%	210,297 $317,000
Q3 2023 Nov 09, 2023	SELL	$1.26 - $2.1 $234,313 - $390,522	-185,963 Reduced 46.47%	214,246 $287,000
Q2 2023 Aug 08, 2023	BUY	$1.56 - $1.84 $356,425 - $420,399	228,478 Added 133.04%	400,209 $720,000
Q1 2023 May 11, 2023	SELL	$1.6 - $2.48 $4,156 - $6,443	-2,598 Reduced 1.49%	171,731 $285,000
Q4 2022 Feb 14, 2023	BUY	$1.68 - $2.5 $4,198 - $6,247	2,499 Added 1.45%	174,329 $335,000
Q3 2022 Nov 10, 2022	BUY	$0.29 - $4.04 $2,734 - $38,101	9,431 Added 5.81%	171,830 $385,000
Q2 2022 Aug 11, 2022	SELL	$3.24 - $5.85 $816 - $1,474	-252 Reduced 0.15%	162,399 $526,000
Q1 2022 May 12, 2022	BUY	$4.6 - $8.83 $56,000 - $107,496	12,174 Added 8.09%	162,651 $856,000
Q4 2021 Feb 10, 2022	BUY	$7.75 - $10.05 $760,275 - $985,905	98,100 Added 187.3%	150,477 $1.28 Million
Q3 2021 Nov 12, 2021	BUY	$7.78 - $10.0 $137,939 - $177,300	17,730 Added 51.17%	52,377 $521,000
Q2 2021 Aug 05, 2021	BUY	$9.22 - $14.48 $319,445 - $501,688	34,647 New	34,647 $323,000

Others Institutions Holding NUVB

# of Institutions

159

Shares Held

157M

Call Options Held

3.2K

Put Options Held

98.7K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $582M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Nuvation Bio Inc. Transaction History